The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells

被引：7
|
作者：
Na, Yu Ran [1 ]
Kim, Jin Young [2 ]
Song, Chang Ho [1 ]
Kim, Mikyung [3 ]
Do, Yen Thi [1 ]
Vo, Tam Thuy Lu [3 ]
Choi, Eunsom [1 ]
Ha, Eunyoung [3 ]
Seo, Ji Hae [3 ]
Shin, So-Jin [1 ]
机构：
[1] Keimyung Univ, Sch Med, Dept Gynecol & Obstet, Daegu 42601, South Korea
[2] Keimyung Univ Sch Med, Dept Internal Med, Daegu 42601, South Korea
[3] Keimyung Univ Sch Med, Dept Biochem, Daegu 42601, South Korea
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 19期
基金：
新加坡国家研究基金会;
关键词：
AZD4547; cancer stem cells; fibroblast growth factor; fibroblast growth factor receptor; ovarian cancer; FACTOR RECEPTOR FAMILY; ADVANCED SOLID TUMORS; LUNG-CANCER; SELECTIVE INHIBITOR; POTENT; AMPLIFICATION; CHEMOTHERAPY; MECHANISMS; DISCOVERY; SAFETY;
D O I：
10.3390/ijms221910817
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The dysregulation of fibroblast growth factor (FGF) signaling has been implicated in tumorigenesis, tumor progression, angiogenesis, and chemoresistance. The small-molecule AZD4547 is a potent inhibitor of FGF receptors. This study was performed to investigate the antitumor effects and determine the mechanistic details of AZD4547 in ovarian cancer cells. AZD4547 markedly inhibited the proliferation and increased the apoptosis of ovarian cancer cells. AZD4547 also suppressed the migration and invasion of ovarian cancer cells under nontoxic conditions. Furthermore, it attenuated the formation of spheroids and the self-renewal capacities of ovarian cancer stem cells and exerted an antiangiogenic effect. It also suppressed in vivo tumor growth in mice. Collectively, this study demonstrated the antitumor effect of AZD4547 in ovarian cancer cells and suggests that it is a promising agent for ovarian cancer therapy.
引用
收藏
页数：15
相关论文
共 50 条
  • [21] Combining the pan-FGFR inhibitor AZD4547 with radiation in lung and head and neck squamous cell carcinoma
    Baschnagel, Andrew M.
    Li, Chunrong
    Morgan, Alecia M.
    Brennan, Sean R.
    Russo, Kalley A.
    Harari, Paul M.
    CANCER RESEARCH, 2017, 77
  • [22] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Qingxia Zhao
    Amanda B. Parris
    Erin W. Howard
    Ming Zhao
    Zhikun Ma
    Zhiying Guo
    Ying Xing
    Xiaohe Yang
    Scientific Reports, 7
  • [23] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Zhao, Qingxia
    Parris, Amanda B.
    Howard, Erin W.
    Zhao, Ming
    Xing, Ying
    Ma, Zhikun
    Yang, Xiaohe
    CANCER RESEARCH, 2017, 77
  • [24] FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial-mesenchymal transition to gefitinib
    Luo, Hong
    Quan, Jin
    Xiao, He
    Luo, Jia
    Zhang, Qin
    Pi, Guocheng
    Ye, Yunfei
    He, Rong
    Liu, Yun
    Su, Xiaona
    Zhao, Lianhua
    Wang, Ge
    ONCOLOGY REPORTS, 2018, 39 (05) : 2270 - 2278
  • [25] FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
    Zhao, Qingxia
    Parris, Amanda B.
    Howard, Erin W.
    Zhao, Ming
    Ma, Zhikun
    Guo, Zhiying
    Xing, Ying
    Yang, Xiaohe
    SCIENTIFIC REPORTS, 2017, 7
  • [26] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (vol 13, 3246, 2022)
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I.
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Ferguson, V.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [27] Selective FGFR inhibitor, AZD4547, modulates bone microenvironment by suppressing RNAKL/M-CSF/Osteocalcine induced osteoclastogenesis in FGFR-amplified breast cancer
    Choi, Y. J.
    Kang, J.
    Lee, H. J.
    Jo, U.
    Park, S. I.
    Bae, J. W.
    Park, K. H.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S118 - S119
  • [28] Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
    Smyth, Elizabeth Catherine
    Turner, Nicholas C.
    Peckitt, Clare
    Pearson, Alex
    Brown, Gina
    Chua, Sue
    Gillbanks, Angela
    Johnston, Stephen R. D.
    Tarazona, Noelia
    Cutts, Ros
    Kilgour, Elaine
    Rooney, Claire
    Smith, Neil R.
    Sumpter, Katherine Anne
    Ajaz, Mazhar A.
    Thomas, Anne L.
    Watkins, David
    Chau, Ian
    Popat, Sanjay
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer
    Aytatli, Abdulmelik
    Barlak, Neslisah
    Sanli, Fatma
    Caglar, Hasan Onur
    Gundogdu, Betul
    Tatar, Arzu
    Ittmann, Michael
    Karatas, Omer Faruk
    CELLULAR ONCOLOGY, 2022, 45 (01) : 41 - 56
  • [30] In Vitro and in Vivo Efficacy of AZD9291 Is Enhanced by Combination with AZD4547 in EGFR Mutant Lung Cancer Cells
    Chan, Daniel C.
    Hinz, Trista K.
    Marek, Lindsay A.
    Zhang, Zhiyong
    Nguyen, Teresa T.
    Bunn, Paul A., Jr.
    Heasley, Lynn
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S580 - S581
12345